The present disclosure relates to compositions and methods for inhibiting the growth of, decreasing the amount of, and abolishing the growth of mutans streptococci.

A hair cosmetic composition including components (A) to (C), wherein the content of component (A) is 0.01 to 5.00% by mass and the content of component (B) is 5.00 to 96.77% by mass: (A) an epoxyaminosilane copolymer, which is a reaction product of compounds (a) to (d): (a) a polysiloxane having two or more oxiranyl groups or oxetanyl groups; (b) a polyether having two or more oxiranyl groups or oxetanyl groups; (c) aminopropyltrialkoxysilane; (d) a specific amine; (B) a micelle formation inhibitor selected from (b1) to (b3): (b1) an organic compound having a solubility parameter δ.sub.H of 10.0 to 15.8 MPa.sup.1/2, excluding (b3); (b2) a compound selected from ethanol and the like; (b3) an organic salt; (C) water.

A hair cosmetic composition including components (A) to (C), wherein the content of component (A) is 0.01 to 5.00% by mass and the content of component (B) is 5.00 to 96.77% by mass: (A) an epoxyaminosilane copolymer, which is a reaction product of compounds (a) to (d): (a) a polysiloxane having two or more oxiranyl groups or oxetanyl groups; (b) a polyether having two or more oxiranyl groups or oxetanyl groups; (c) aminopropyltrialkoxysilane; (d) a specific amine; (B) a micelle formation inhibitor selected from (b1) to (b3): (b1) an organic compound having a solubility parameter δ.sub.H of 10.0 to 15.8 MPa.sup.1/2, excluding (b3); (b2) a compound selected from ethanol and the like; (b3) an organic salt; (C) water.

Disclosed are methods improving or stimulating hair regeneration; treating, inhibiting, or reducing hair loss; improving or stimulating hair growth; treating, inhibiting, or reducing pigmentation loss; and/or improving or stimulating pigmentation production in a subject with one or more autophagy inducing agents.

The use of PREVORA brand topical dental solution (100 mg/ml chlorhexidine) sold by CHX Technologies, Inc., Toronto, Canada, to treat and/or prevent the advance of both dental decay (caries) and periodontal disease, simultaneously and in one procedure, that can easily be accomplished by a dental professional or a medical assistant. Chronic periodontitis and/or caries, the result of an imbalance of the microbial composition of the biofilm on the teeth, at the gum line or under the gum line, can be treated by the application of PREVORA, following standard oral cleaning and debriding of plaque at or below the gum line, to restore the balance of the biofilm to more normal, symbiotic composition. This treatment method is particularly useful in conjunction with the medical management of chronic diseases, such as type 2 diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and the like, which have been associated with periodontopathogens. As an example, the topical dental solution is applied to the teeth of an adult diabetic patient every 3 months for the first year, followed by semi-annual single applications for as long as the patient remains at risk for either periodontal disease or caries.

The use of PREVORA brand topical dental solution (100 mg/ml chlorhexidine) sold by CHX Technologies, Inc., Toronto, Canada, to treat and/or prevent the advance of both dental decay (caries) and periodontal disease, simultaneously and in one procedure, that can easily be accomplished by a dental professional or a medical assistant. Chronic periodontitis and/or caries, the result of an imbalance of the microbial composition of the biofilm on the teeth, at the gum line or under the gum line, can be treated by the application of PREVORA, following standard oral cleaning and debriding of plaque at or below the gum line, to restore the balance of the biofilm to more normal, symbiotic composition. This treatment method is particularly useful in conjunction with the medical management of chronic diseases, such as type 2 diabetes, chronic obstructive pulmonary disease, cardiovascular disease, and the like, which have been associated with periodontopathogens. As an example, the topical dental solution is applied to the teeth of an adult diabetic patient every 3 months for the first year, followed by semi-annual single applications for as long as the patient remains at risk for either periodontal disease or caries.

A method of reducing staining by an oral care composition, including providing an effective amount of a metal chelator, wherein the oral care composition includes chlorhexidine.

A method of reducing staining by an oral care composition, including providing an effective amount of a metal chelator, wherein the oral care composition includes chlorhexidine.

An object of the present invention is to provide a composition that can be used as a novel anti-inflammatory agent. An inflammation such as stomatitis, oral mucositis, gingivitis, or pneumonia can be ameliorated and/or prevented by using a composition comprising olanexidine or a pharmacologically acceptable salt thereof. The composition of the present invention preferably further comprises a poloxamer which is a block copolymer consisting of a chain of polyoxypropylene (POP) and two chains of polyoxyethylene (POE) flanking the POP.

To provide an inhibitor of melanin decomposition, which inhibits decomposition of melanin in keratinocytes to accelerate accumulation of melanin in skin and hair. An inhibitor of melanin decomposition in keratinocytes, comprising at least one selected from the group consisting of a plant extract containing berberine or a salt thereof, berberine or a salt thereof, proguanil or a salt thereof and phenformin or a salt thereof, as an active ingredient.